Henry Ford Health

Henry Ford Health Scholarly Commons
Radiation Oncology Articles

Radiation Oncology

9-1-2022

The 2021 landscape of FDA-approved artificial intelligence/
machine learning-enabled medical devices: An analysis of the
characteristics and intended use
Simeng Zhu
Marissa Gilbert
Indrin J. Chetty
Farzan Siddiqui

Follow this and additional works at: https://scholarlycommons.henryford.com/radiationoncology_articles

International Journal of Medical Informatics 165 (2022) 104828

Contents lists available at ScienceDirect

International Journal of Medical Informatics
journal homepage: www.elsevier.com/locate/ijmedinf

The 2021 landscape of FDA-approved artificial intelligence/machine
learning-enabled medical devices: An analysis of the characteristics and
intended use
Simeng Zhu, Marissa Gilbert, Indrin Chetty, Farzan Siddiqui *
Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI, USA

A R T I C L E I N F O

A B S T R A C T

Keywords:
Medical device
Artificial intelligence
Machine learning

Background: Machine learning (ML), a type of artificial intelligence (AI) technology that uses a data-driven
approach for pattern recognition, has been shown to be beneficial for many tasks across healthcare. To char
acterize the commercial availability of AI/ML applications in the clinic, we performed a detailed analysis of AI/
ML-enabled medical devices approved/cleared by the US Food and Drug Administration (FDA) by June 2021.
Methods/Materials: The publicly available approval letters by the FDA on 343 AI/ML-enabled medical devices
compiled by the agency were reviewed. The characteristics of the devices and the patterns of their intended use
were analyzed, and basic descriptive statistical analysis was performed on the aggregated data.
Results: Most devices were reviewed by radiology (70.3%) and cardiovascular (12.0%) medical specialty panels.
The growth of these devices sharply rose since the mid-2010s. Most (95.0%) devices were cleared under the 510
(k) premarket notification pathway, and 69.4% were software as a medical device (SaMD). Of the 241 radiologyrelated devices, the most common applications were for diagnostic assistance (48.5%) and image reconstruction
(14.1%). Of the 117 radiology-related devices for diagnostic assistance, 20.5% were developed for breast lesion
assessment and 14.5% for cardiac function assessment on echocardiogram. Of the 41 cardiology-related devices,
the most common applications were electrocardiography-based arrhythmia detection (46.3%) and hemody
namics & vital signs monitoring (26.8%).
Conclusion: In this study, we characterized the patterns and trends of AI/ML-enabled medical devices approved or
cleared by the FDA. To our knowledge, this is the most up-to-date and comprehensive analysis of the landscape as
of 2021.

1. Introduction

While most studies in this area focused on developing and validating
AI/ML algorithms for their respective use cases, few have investigated
the degree to which the growing progress in AI/ML research has been
translated into commercially available tools for clinics [8–11]. In the
United States, when a device (including software) is intended to di
agnose, mitigate, treat, cure, or prevent a disease, it is considered a
medical device and must be approved or cleared in a risk-stratified
fashion (Table 1) by the Center for Devices and Radiological Health of
the US Food and Drug Administration (FDA), the regulatory agency
responsible for certifying the commercial distribution of the devices.
To characterize the AI/ML medical device landscape as of 2021, we
performed an in-depth analysis of the recently published list by the FDA
of 343 AI/ML-enabled medical devices cleared or approved as of June
2021 [14] (to reduce redundancy, we will refer to both FDA-cleared and

Artificial Intelligence and machine learning (AI/ML) algorithms,
with their ability to automatically recognize and learn patterns from
data, have recently emerged as a promising technology that can
potentially leverage the recent advancement in “big data” to allow more
efficient and precise delivery of healthcare [1–3].
Research studies involving AI/ML algorithms for problems in health
and medicine grew sharply in the past decade [4], a period in which
three significant enabling events occurred: the advancement of the field
of deep learning [5], digitization of healthcare data in massive quanti
ties [6], and the growing availability of advanced hardware equipped
with computational capabilities powerful enough for developing AI/ML
algorithms [7].
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intended use: diagnostic and triage assistance, image reconstruction,
image segmentation and labeling, imaging device, radiation therapy
planning, image storage and process software, surgery planning, image
acquisition assistance, image registration, patient positioning, and
linear accelerator. In addition, we further classified the radiology de
vices within the “diagnostic and triage assistance” category based on the
type of abnormality or lesion. For cardiovascular devices, we created
five categories based on their intended use: electrocardiography (ECG)based arrhythmia detection, hemodynamic & vital signs monitoring,
stethoscope-based auscultation analysis, coronary artery disease detec
tion, and others. These categories for radiology and cardiovascular de
vices were created by the authors to efficiently classify these devices
based on their intended uses and product codes with the goal of using as
few mutually exclusive categories as possible.
Finally, we performed various basic descriptive statistical analyses
for the aggregated data.

Table 1
Summary of the risk-based medical device regulation by the US Food and Drug
Administration.
Definition and Regulatory Pathways for Medical Devices of Different Classes

Class I
Class II
Class III

Definition

Possible regulatory
pathways (if not
except)

Low- to moderate-risk medical
devices under general controls by
the FDA*
Moderate- to high-risk medical
devices under general controls and
Special Controls
High-risk medical devices (which
typically support or sustain human
life) under general controls and
Premarket Approval (PMA)

510(k) premarket
notification, De Novo
request
510(k) premarket
notification, De Novo
request
Premarket approval

Common Regulatory Pathways for Medical Devices by the FDA
Premarket
The most stringent type of submission application for which all
approval [12]
nonclinical and clinical studies supporting the safety and
effectiveness of the medical devices are required. A successful
application results in “approval” of the new device by the FDA.
510(k) premarket
Submission pathway aiming to demonstrate that a new device
notification [12]
is as safe and effective as, or substantially equivalent to, a
legally marketed device (referred to as a predicate device). A
successful application results in “clearance” of the new device
by the FDA.
De Novo request
Submission pathway for novel class I and II medical devices for
[13]
which there are no legally marketed predicate devices.

2.3. Assessment of medical AI/ML-related research activity
Since academic research is an important driving factor for in
novations in industry, the trend of research output of medical AI/ML
was assessed. PubMed was queried for the number of AI/ML-related
scientific papers published annually, and a scatterplot was generated
to assess the temporal trend. The following keywords were used during
the PubMed search query: (“machine learning” OR “artificial intelli
gence”) AND (“medicine” OR “medical” OR “clinical” OR “healthcare”).

*FDA = Food and Drug Administration.

3. Results

-approved devices as “approved” for the rest of the manuscript).

3.1. Overall characteristics of the devices

2. Materials and methods

A total of 343 medical devices were included for analysis (raw data
and the database that we created can be found in Appendix A). Seven
(2.0%) devices were approved before 2010, and the numbers of ap
provals increased in consecutive years since then, except from 2014 to
2015 (Fig. 1). The numbers of approvals from 2016 to 2021 were 16
(4.7%), 26 (7.6%), 61 (17.8%), 75 (21.9%), 100 (29.2%), and 38
(11.1%), respectively (Fig. 1). Of note, the number of approvals for the
year 2021 is lower than the actual amount since the list of AI/MLenabled devices did not include those approved after June 2021.
All 343 devices were classified as class II by the FDA, and no device
was considered implanted or life-sustaining/support device. Three
hundred and twenty-six (95.0%) devices were approved under the 510
(k) premarket notification process, followed by De Novo request (n = 16,
4.7%) and premarket approval (n = 1, 0.3%) (Table 2). Two hundred
and thirty-eight (69.4%) devices were software as a medical device
(SaMD). The FDA approval summaries of 152 (44.3%) devices did not
mention AI or specify any specific AI algorithm. Fifty-four (39.9%)
mentioned “AI” only, and 137 specified the types of algorithms in more
detail than “AI” (examples include “machine learning”, “convolutional
neural network”, “deep learning”). Forty-four (12.8%) devices were
enabled for use on mobile devices. Clinician, patient, and both were the
primary users for 322 (93.9%), 10 (2.9%), and 11 (3.2%) devices,
respectively.
The most common product codes were LLZ (medical image man
agement and processing system), JAK (computed tomography x-ray
system), QAS (radiological computer-aided triage and notification
software), QIH (medical image management and processing system),
and IYN (ultrasonic pulsed Doppler imaging system), each with 91
(26.5%), 27 (7.8%), 21 (6.1%), 14 (4.0%), and 13 (3.8%) devices,
respectively.
Each device was assigned one lead medical specialty review panel.
The involved panels (with numbers of approved devices) include radi
ology (n = 241, 70.3%), cardiovascular (n = 41, 12.0%), hematology (n
= 13, 3.8%), neurology (n = 12, 3.5%), ophthalmic (n = 6, 1.7%),
general and plastic surgery (n = 5, 1.5%), clinical chemistry (n = 5,

2.1. Source of data
In September 2021, the United States FDA’s Digital Health Center of
Excellence published a list consisting of 343 AI/ML-enabled medical
devices approved by the agency as of June 2021 [14]. While the exact
criteria for creating the list were not specified, the FDA website defined
artificial intelligence as “a device or product that can imitate intelligent
behavior or mimic human learning and reasoning” [15].
The list contains basic information for each device, including the
decision date for approval, submission number, name of the device,
name of the company, product code, and the lead medical specialty
review panel. To offer additional insights on the details of the devices,
two research assistants independently reviewed each device’s publicly
available approval letter and recorded the following information in a
database: device class (I, II, or III), submission type (510(k) premarket
notification, De Novo request, or premarket application pathway),
whether the device is implanted, whether the device is life-sustaining/
support, a summary of intended use, whether the device is software
only, the type of AI algorithm used, whether the device can be used in
mobile devices, and primary user (clinician, patient, or both). Conflict
ing information was resolved by discussion until a consensus was
reached. To ensure data consistency, only data from the FDA approval
letters were used for analysis, and no additional information (e.g. mar
keting materials or publications) was sought.
2.2. Further analysis for radiology and cardiovascular devices
An initial inspection of the original list revealed that “radiology” and
“cardiovascular” represent the two most common medical specialty re
view panels. To further characterize the trends and patterns of functions
of the devices in these two categories, we performed additional cate
gorization and subcategorization based on the devices’ intended use. For
radiology devices, we created 11 main categories based on their
2
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Fig. 1. The number of FDA-approved AI/ML-enabled medical devices per year.
Table 2
General characterizes of the AI/ML-enabled medical devices.
Class of Device

N = 343

%

I
II
III

0
343
0

0
100
0

Type of Submission
510(k) premarket notification
De Novo request
Premarket approval

326
16
1

95.0
4.7
0.3

Algorithm description
Did not specify
Mentioned “AI” only
Mentioned specific algorithm beyond “AI”

152
54
137

44.3
15.7
39.9

Software Only
Yes
No

238
105

69.4
30.6

Fig. 2. Lead medical specialty review panels for the AI/ML-enabled devices.

Mobile Application
Yes
No

44
299

12.8
87.2

with the approval of Viz.AI Inc.’s ContaCT product [17], has been used
as the primary product code for 20 other devices included in this study.

Type of User
Clinician
Patient
Combination

322
10
11

93.9
2.9
3.2

3.2. Details of radiology devices
Among the 241 devices approved by radiology as the lead panel, the
most common application was for diagnostic and triage assistance, ac
counting for 117 (48.5%) devices, followed by 34 (14.1%) for image
reconstruction, 27 (11.2%) for image segmentation and labeling, 16
(6.6%) for imaging devices, and 15 (6.2%) for radiation therapy plan
ning (Table 3). Of the 117 devices intended for diagnostic and triage
assistance, 24 (20.5%), 17 (14.5%), 13 (11.1%), 11 (9.4%), and 9 (7.7%)
were developed for the assessment of breast lesions, cardiac function on
echocardiogram, intracranial hemorrhage, stroke, and pulmonary
nodule, respectively (Table 3).

1.5%), microbiology (n = 5, 1.5%), gastroenterology-urology (n = 4,
1.2%), anesthesiology (n = 4, 1.2%), general hospital (n = 3, 0.9%),
obstetrics and gynecology (n = 1, 0.3%), orthopedic (n = 1, 0.3%),
dental (n = 1, 0.3%), and pathology (n = 1, 0.3%) (Fig. 2). Out of the 19
total medical specialty panels for medical device classification at the
FDA, all but 4 were represented, with the exception of chemistry,
immunology, physical medicine, and toxicology [16].
The 16 devices approved under the De Novo request pathway
represent 8 unique specialties (details can be found in the Supplemental
Materials). Of the 16 new product codes created by this mechanism, 8
were used for 510(k) clearances among the remaining devices in this
study, with each code used by a median of 2 (range, 1–20) other devices.
The most notable example is the product code QAS (radiological
computer-assisted triage and notification software), created in 2018

3.3. Details of cardiovascular devices
Of the 41 devices approved by cardiology as the lead panel, the most
common applications were ECG-based arrhythmia detection (n = 19,
46.3%) and hemodynamics & vital signs monitoring (n = 11, 26.8%)
3
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accelerated growth beginning in the mid-2010 s.

Table 3
Intended use for radiology-related AI/ML-enabled medical devices.
Categories for
intended use

Subcategory (if
available)

Diagnostic and triage
assistance

Image reconstruction
Image segmentation and
labeling
Imaging device
Radiation therapy
planning
Image storage and
processing
Surgery planning
Image acquisition
assistance
Image registration
Patient positioning
Linear accelerator

4. Discussion

Number and percentage
of devices

AI/ML technologies experienced significant growth in the past
decade and are starting to impact multiple industries, including
healthcare. To describe the characteristics of AI/ML-enabled medical
devices currently approved for marketing in the US, we performed a
thorough analysis of such devices approved by the FDA up to mid-2021.”

117 (48.5%)
Breast lesion detection
Echocardiogram analysis
Intracranial hemorrhage
detection
Stroke detection
Pulmonary nodule
detection
Fracture detection
Pneumothorax detection
Pulmonary embolism
detection
Others

24 (20.5%)
17 (14.5%)
13 (11.1%)
11 (9,4%)
9 (7.7%)

4.1. Comparison to prior studies

7 (6.0%)
4 (3.4%)
2 (1.7%)

The scope of the devices included for analysis in this study is broader
than those used in similar efforts in the past – we included devices
considered to be “AL/ML-enabled” by the FDA’s Digital Health Center of
Excellence, whereas the ones in prior studies were “AI/ML-based”,
generally limited to those with wordings such as “machine learning”,
“neural network”, and “artificial intelligence” in public FDA documents
[8–11]. As shown by results in Section 3.1, the reports for 152 (44.3%)
AI/ML-enabled devices in our study did not mention any AI/ML-related
keywords, suggesting that AI/ML might not be the principal focus for
these devices. The expanded timeline and broader inclusion criteria
make the current study the most comprehensive thus far (Table 5). In
addition, compared to previous studies, we performed a more in-depth
categorization of the intended uses for devices reviewed by radiology
and cardiovascular panels at the FDA.

30 (25.6%)
34 (14.1%)
27 (11.2%)
16 (6.6%)
15 (6.2%)
12 (5.0%)
8 (3.3%)
4 (1.7%)
4 (1.7%)
3 (1.2%)
1 (0.4%)

4.2. Comparison to research output

Note: The percentages (in italics) reported for subcategories of diagnostic and
triage assistance were calculated with respect to 117, the total number of devices
within this main category.

Our results showed that the number of approved AI/ML-enabled
devices has been consistently increasing since the mid-2010 s, concor
dant with prior findings [8–11], and a similar pattern was observed in
the growth of AI/ML-related medical research (Fig. 3). The similarity of
growth patterns suggests the responsiveness of industry and regulatory
bodies to translate AI/ML medical research into commercially available
products. The rapid growth of AI/ML research and medical device
development since the mid-2010 s can be likely attributed to the pub
lication of two landmark papers: Krizhevsky et al.’s pioneering work on
AlexNet in 2012 [19], which popularized the use of convolutional neural
networks for image processing tasks, and Ronneberger et al.’s impactful
work on U-Net in 2015, which was specifically designed for medical
image segmentation, an important task in medical image processing
[20].
Another interesting observation from our results was that, of the FDA
documents that mentioned specific types of AI/ML algorithms in use,
they were predominantly deep convolutional neural networks, the most
common type of algorithms used for image-based tasks [5]. This is
consistent with the fact most intended uses for the devices were imagebased tasks, such as image classification and segmentation. Other pop
ular machine learning algorithms, such as transformers [21] and long
short-term memory (LSTM) [22], have not been commonly incorporated
in the FDA approved devices.

Table 4
Intended use for cardiovascular AI/ML-enabled medical devices.
Categories for intended use

Number and percentage of devices

ECG-based arrythmia detection
Hemodynamics & vital signs monitoring
Stethoscope-based auscultation analysis
Coronary artery disease detection
Others

19 (46.3%)
11 (26.8%)
4 (9.8%)
3 (7.3%)
4 (9.8%)

Abbreviations: ECG = electrocardiogram.

(Table 4).
3.4. Mobile and patient-use devices
The 44 devices enabled for mobile devices represent 9 medical spe
cialties, with radiology (n = 13, 29.5%), cardiovascular (n = 11, 25.0%),
neurology (n = 6, 13.6%) and clinical chemistry (n = 4, 9.1%) being the
most common. The 21 devices intended (whether exclusively or not) for
patient use represent 7 specialties, with cardiovascular (n = 10, 47.6%),
general hospital (n = 3, 7.3%), and hematology (n = 3, 7.3%) being the
most common. Compared with the distribution of medical specialties for
the entire cohort of devices, the distributions for these two subsets are
more evenly distributed.
In addition, there is a high degree of overlap between the 44 mobileenabled and 21 patient use devices, with 12 that fall into both categories
simultaneously. Of these 12 devices, the most common intended uses
were diabetes care-related (n = 5), ECG-based arrythmia detection (n =
2), and stethoscope-based cardiac auscultation (n = 2).

4.3. Medical specialties
Not surprisingly, 82% of the approved devices were related to radi
ology and cardiology. The concentration of AI/ML-enabled devices in
these two medical specialties can be likely explained by the heavy use of
digital medical data (such as digital medical imaging data and electro
cardiogram) and the significant role played by pattern recognition in
making diagnoses. A similar trend was observed in a recent bibliometric
study which showed that, in 83,979 scientific articles on AI/ML in the
field of medicine, the four most common medical specialties were
radiology, oncology, neuroimaging, and ophthalmology (in descending
order) [23].
One of the possible key driving factors making radiology the leader

3.5. Medical AI/ML-related research activity
The numbers of annually published AI/ML-related scientific papers
for years 2010 to 2021 were shown in Fig. 3, which demonstrated an
4
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Fig. 3. The temporal growth of published medical AI/ML scientific papers.

America/American College of Radiology/National Academy of Medi
cine workshop on the roadmap for research on AI/ML in medical im
aging are critical for setting priorities and building collaborative efforts
among various stakeholders of radiology [26].
In the analysis of the distribution of represented medical specialties,
it is interesting to note that pathology, another specialty that was ex
pected to be impacted by the development of AI/ML algorithms along
with radiology [27], only has one approved device. (We are aware of the
recent approval of the second device in this category, Paige Prostate by
Paige.AI, in September 2021; however, to keep our discussion consis
tent, we are excluding it from our analysis.) Although lacking value
determination and reimbursement structures have been proposed as
potential reasons for the slow adoption of digital pathology [3,28], it is
beyond the scope of the current work to investigate the scientific or
regulatory factors that contributed to the low number of pathologyrelated AI/ML devices. We hope future work will shed light on this
curious area.
Lindsell et al. proposed that AI/ML algorithm development should be
“about matching the algorithm to the problem, and not the other way”
[29]. While our data is not suited to assess this criterion on the AI/MLenabled devices, we performed a detailed analysis of the intended uses
for radiology and cardiovascular devices. We showed that, of the 241
radiology-related devices, they were well balanced between those
assisting diagnosis/triage (48%) and those for image processing and
manipulation (52%). Of the 117 radiology devices approved for assisting
diagnosis/triage, the most common indication was for breast lesion
detection (21%), one of the most common anatomic sites for diagnostic
imaging. Of the 41 cardiovascular devices, almost half (46%) were
developed for arrhythmia detection on ECG, the most performed diag
nostic procedure in cardiovascular medicine. Although rule-based al
gorithms to automatically interpret ECGs have existed for decades, the
clinical adoption has been low due to poor accuracy; however, the
application of deep learning for this purpose has significantly improved
the accuracy [30].

Table 5
Comparison between the current study and prior investigations.
Study

Inclusion criteria for devices

Time frame of
FDA approval

Number of
devices

Benjamens et al.
[8]

Official FDA announcement
contains any of the following
expressions: “machine
learning”, “deep learning”,
“deep neural networks”,
“artificial intelligence”, “AI”
FDA documents contain any
of the following expressions:
“artificial intelligen*”,
“machine learning”, “deep
learning”, “neural network”,
“convolutional neural,
algorithm”
Internet web pages contain:
(“artificial intelligence” OR
“ai” OR “machine learning”
OR “deep learning”) AND
(“FDA approved” OR “FDA
approves” OR “FDA
approval”)
FDA documents containing
“AI keywords”, devices
included in Benjamens et al.’s
work [8], and an online
database maintained by the
American College of
Radiology [18]
“AI/ML-Enabled” as
determined by the FDA’s
Digital Health Center of
Excellence

January 2010 March 2020

29

January 2015 March 2020

222 (US),
240
(Europe)

Up until
February 2020

49

January 2015 December
2020

130

Up until June
2021

343

Muehlematter
et al.[9]

Lyell et al.[10]

Wu et al.[11]

Our study

in the development of AI/ML-enabled devices is that many pioneering
experts recognized at a very early phase of the recent “AI revolution” the
opportunity to apply the advancement made in the realm of AI/ML al
gorithms to the workflow of radiology [24,25]. The computer vision
tasks in which modern AI/ML algorithms excel (e.g. image classification,
image segmentation, object detection) bear a strong resemblance to
many daily tasks of a diagnostic radiologist. In addition, efforts like the
2018 National Institute of Health/Radiological Society of North

4.4. Regulatory considerations
Due to the relative lenient regulatory process, 510(k) clearance is the
most common pathway for medical devices in the US, with about 96%
devices cleared under this mechanism [31]. Our cohort had a similar
5
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proportion of 95%. However, when vendors try to market novel devices
with no available predicate device for the 510(k) pathway, they would
have to undergo the De Novo request process (Table 1). As shown in
Section 3.1, of the newly created product codes from the 16 De Novo
devices in this study, QAS gets used the most frequently by later 510(k)
clearances, and most of these devices are designed for detecting intra
cranial hemorrhages (ICH). The underlying reason for the high number
of devices under this product code is likely multifactorial: (1) with a high
fatality rate if undetected, ICH is an emergent condition where a timely
interpretation of the radiologic image is critical, hence there is a clinical
need for rapid triage of scans, (2) deep learning has been shown to be an
effective method for detecting ICHs, with reported area under the ROC
curves ranging from 0.85 to 0.99 [32,33].
While this study is focused entirely on FDA-approved AI/ML devices,
Muehlematter et al. compared the 222 FDA-approved devices in the US
and 240 CE-marked devices in Europe [9]. One observation of interest
was that, of the 124 devices commonly approved in both continents, the
majority (80) were first approved in Europe, suggesting potentially
relatively less rigorous evaluation in Europe. This could be a topic of
interest for future investigations.

6. Summary table
6.1. What was already known on this topic
• The development of AI/ML algorithms for healthcare applications
has significantly grown in the past decade.
• Approval or clearance by the FDA is required for a medical device to
be commercialized in the US.
6.2. What this study added to our knowledge
• Most of the AI/ML-enabled medical devices approved or cleared by
the FDA are in the field of radiology and cardiovascular medicine.
• The number of AI/ML-enabled medical devices approved or cleared
per year largely reflects the increase in research output.
• The indications for these devices generally reflect areas of clinical
need.
Author contributions
S.Z. conceived of the presented idea. S.Z. and M.G. performed the
data acquisition and analysis. I.C. and F.S. verified the analytical
methods. S.Z. wrote the manuscript with support from M.G.. I.C. and F.S.
supervised the project.

4.5. Strengths, limitations, and future directions
This study analyzed the characteristics and intended use of 343 AI/
ML-enabled medical devices approved by the FDA as of June 2021.
Compared to prior published studies on this topic so far [8–11], the list
of devices included in this study is the most exhaustive and up-to-date,
and our categorization on the intended use is the most detailed as we
further investigated the categories and subcategories within the two
most common medical specialties (radiology and cardiovascular) that
constitute 82.3% of the approved devices. In addition, our data source is
homogeneous because the list of the devices was compiled by the FDA
and the analysis was based solely on the documents from the agency.
Our study has several limitations. First, our analysis was based
entirely on the publicly available FDA approval letters for medical de
vices which were considered “AI/ML-enabled” by the agency. While the
intent of this practice to ensure data consistency, many additional
insightful information (such as details of the algorithms and their per
formance results) and devices approved after June 2021 could not be
considered. Second, although FDA approval status allows commercial
distribution, we cannot determine the actual levels of availability and
clinical deployment in healthcare facilities, making it difficult to assess
the real-world impact of AI/ML devices. Third, our analysis was limited
to devices approved by the FDA, thereby reducing the generalizability of
our conclusions.
To provide the general medical community and patients with
fundamental information on the current landscape of this the approved
AI/ML devices, we limited the scope of this study to an overall charac
terization of such devices without delving into details beyond the FDA
documents. We hope this study could aid future investigations on more
in-depth topics of interest. Potential future directions may include
assessment of the clinical impacts made by AI/ML devices, optimal
workflow integration for these devices, comparison of the AI/ML algo
rithms deployed in the devices, experience of the users (healthcare
providers and/or patients) of these devices, etc.

Appendix A. Supplementary material
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijmedinf.2022.104828.
References
[1] K.-H. Yu, A.L. Beam, I.S. Kohane, Artificial intelligence in healthcare, Nat. Biomed.
Eng. 2 (2018) 719–731, https://doi.org/10.1038/s41551-018-0305-z.
[2] F. Jiang, Y. Jiang, H. Zhi, et al., Artificial intelligence in healthcare: past, present
and future, Stroke Vasc. Neurol. 2 (2017) 230–243, https://doi.org/10.1136/svn2017-000101.
[3] Rajpurkar P, Chen E, Banerjee O, et al. AI in health and medicine. Nat Med
Published Online First: 20 January 2022. doi:10.1038/s41591-021-01614-0.
[4] B.X. Tran, G.T. Vu, G.H. Ha, et al., Global evolution of research in artificial
intelligence in health and medicine: a bibliometric study, J. Clin. Med. 8 (2019)
E360, https://doi.org/10.3390/jcm8030360.
[5] Y. LeCun, Y. Bengio, G. Hinton, Deep learning, Nature 521 (2015) 436–444,
https://doi.org/10.1038/nature14539.
[6] V. Tresp, J. Marc Overhage, M. Bundschus, et al., Going digital: a survey on
digitalization and large-scale data analytics in healthcare, Proc. IEEE 104 (2016)
2180–2206, https://doi.org/10.1109/JPROC.2016.2615052.
[7] K.-S. Oh, K. Jung, GPU implementation of neural networks, Pattern Recogn. 37
(2004) 1311–1314, https://doi.org/10.1016/j.patcog.2004.01.013.
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